Skip to main content
. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016

Table 5. . Overall and progression-free survival (all patients).

Cohort A (metformin) Cohort B (no metformin)
Overall survival

42.8% patients alive at 1 year 32.7% patients alive at 1 year

28.5% patients alive at 2 years 26.2% patients alive at 2 years

Progression-free survival

15.5% patients free from progression at 1 year
-10.3% patients free from progression at 2 years
16.5% patients free from progression at 1 year
5.5% patients free from progression at 2 years